BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025
Update: 2025-07-23
Description
In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and EHA meetings, including:
- The randomized phase III FLAIR trial
- The randomized phase III SEQUOIA trial
- The randomized phase III BRUIN CLL-321 trial
Presenters:
James Davis, PharmD, BCOP
Clinical Pharmacy Specialist, Malignant Hematology
MUSC Hollings Cancer Center
Assistant Professor
MUSC College of Pharmacy
Charleston, South Carolina
Victoria Nachar, PharmD, BCOP
Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan
Link to full program:
https://bit.ly/3H2EcSX
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
